IDYA
IDEAYA Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
consensus rating "Buy"
ample liquidity
Net Income Plunges
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About IDYA
Ideaya Biosciences, Inc.
A company that developing oncology therapies for the treatment of cancer using molecular diagnostics
Biological Technology
Invalid Date
05/23/2019
NASDAQ Stock Exchange
131
12-31
Common stock
7000 Shoreline Court, Suite 350, South San Francisco, California 94080
--
IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is an oncology-focused precision medicine company dedicated to discovering and developing targeted therapies for patient populations selected using molecular diagnostics. Their approach combines the broad ability to identify and validate translated biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies they are developing. They are applying these capabilities to a variety of precision medicine, including direct targeting of carcinogenic pathways and synthetic lethality, which represents an emerging class of precision medicine targets.
Company Financials
EPS
IDYA has released its 2025 Q1 earnings. EPS was reported at -0.82, versus the expected -0.69, missing expectations. The chart below visualizes how IDYA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
